The Coloplast Titan 5-Year Mechanical Survival Rate Taught Me How to Buy Medical Devices

A meeting I wasn’t ready for

Last October, our finance director asked a question that made me wish the meeting had run long enough for me to disappear. I had spent two months building a capital-spending spreadsheet for three projects: a digital radiography room, a surgical robot, and a penile implant program built around the Coloplast Titan. The imaging and robot quotes were detailed down to the last service visit. The implant vendor had sent pricing, too. Then the finance director asked, “What’s the 5-year mechanical survival rate on the Coloplast Titan?”

I didn’t know. I knew the price, the warranty period, and the surgeon’s preference. I did not know how often the device itself failed. That is the moment I stopped treating medical devices like office supplies.

Let me back up. I’m the office administrator for a 14-provider urology practice. I manage vendor contracts and nonclinical purchasing—roughly $900,000 per year across about 20 vendors—and I report to operations and finance. When I took over purchasing in 2021, I believed buying for a medical practice was basically buying for any office: gather three quotes, compare like for like, and pick the option that is neither the cheapest nor the flashiest.

That approach worked for paper products. It failed, in different ways, with digital radiography, a surgical robot, and the Coloplast Titan.

The imaging project and the “what is digital radiography?” moment

In early 2024, our main clinic finally scheduled a replacement for its old computed radiography room. For years, the technologists had been using cassette-based plates and a separate reader. When I called the first imaging vendor, their rep asked whether I meant computed radiography or direct radiography. I honestly did not know there were two kinds.

So I did what any slightly embarrassed administrator does: I searched online for “what is digital radiography?” before our next meeting. The short answer: computed radiography, or CR, uses a reusable phosphor plate that a technologist feeds through a reader. Digital radiography, or DR, uses a flat-panel detector, and the image appears on a nearby workstation within seconds. It sounds like a small difference until you watch staff carry cassettes back and forth all day. DR is basically the difference between a film camera and a digital camera, except the sensor is built into the X-ray table or the wall stand.

Then came the price shock. Three quotes for a single-room DR system landed somewhere between $68,000 and $149,000, and that was before detector compatibility, installation, networking, and the service contract. I almost signed the cheapest one. The reseller promised it would work with our PACS and the rest of our medical imaging system, but didn’t put any of that in writing. When accounting asked for an itemized invoice, the salesperson sent a one-line PDF. Finance rejected it, and that took six weeks to sort out. The deal eventually fell apart.

The system we finally bought cost about $25,000 more from a manufacturer rep, but it came with a network diagram, a training schedule, a real service contract, and an invoice our auditors could actually follow. That was my first clue that a medical imaging system purchase is really a systems-integration purchase. If you don’t understand how the pieces connect, the lowest price is just the first bill.

The surgical robot that gave us budget indigestion

The imaging decision was painful in small ways. The robot conversation was painful in a different way.

Robotic prostatectomy kept coming up in our committee meetings. Patients ask about it, and some of our younger surgeons wanted to build a program around it. I don’t have hard data on national robot pricing, so treat these numbers as what we saw in proposals from three vendors: a new system came in between $1.8 million and $2.5 million. The annual service contract was another $150,000 or so. Instruments added hundreds to thousands per case. And none of those quotes included the construction changes we would need in the operating room.

What made it harder is that a surgical robot isn’t really one product. It is capital equipment, software, reusable instruments, training, service, and a steady case volume to make any of it make sense. Our surgeons looked at projected prostatectomy volume and concluded we weren’t there yet. So we deferred it. I remember thinking: okay, so sometimes the best procurement decision is no procurement decision.

That same conversation, though, led directly to the most interesting project on my list.

Then the Coloplast Titan landed on the same worksheet

Prostate cancer treatment changes a man’s life in ways that don’t show up in a surgical brochure. Some men who go through prostatectomy end up with erectile dysfunction that doesn’t respond to medication. For them, a penile implant is not a vanity purchase; it’s the difference between feeling like a patient and feeling like themselves again.

One of our urologists wanted to build a men’s health program around the Coloplast Titan. That’s how I ended up on an evening research spiral with the phrase “coloplast company overview medical devices” in my search history.

The company overview turned out to matter more than I expected. Coloplast started in Denmark in the 1950s after a nurse invented a better ostomy bag. Today the company is still best known for chronic care products: ostomy care, continence care, wound care, and skin care. The Titan comes from its surgical urology business, but the same focus on long-term patient needs runs through the whole company. For a buyer, that said something useful. A device from a company that thinks about patients for decades, not just until the invoice clears, is a different purchase than a device from a company that might not exist in five years.

The phrase that made me a better buyer: “coloplast titan mechanical survival 5 years”

Here is where I circle back to the finance director’s question. I had the Titan listed in my spreadsheet as a product with a price and a delivery estimate. But any urologist will tell you that a three-piece inflatable penile prosthesis has moving parts and pressurized fluid. It is a mechanical device, and mechanical devices sometimes fail.

So I typed the search phrase the same way a worried patient might: “coloplast titan mechanical survival 5 years.” What I found took me a while to digest, and I want to give you the plain-language version.

In the peer-reviewed studies we reviewed, five-year mechanical survival estimates for the Coloplast Titan clustered in the low-to-mid 90 percent range—roughly 95 percent depending on the series. That means about one device in twenty may need a mechanical revision within five years. But you have to read the denominator carefully. “Mechanical survival” does not include every complication. It tracks device-related mechanical failures like leaks or pump malfunctions. It does not include infection, erosion, or removal for other reasons, which are usually reported separately.

That distinction changed how I talk about the product. If I quote “95 percent” in a capital committee meeting without explaining what it includes, I’m not being accurate. I’m being lazy. The number is still useful, but only when I define it.

Our lead urologist put it simply: “The Titan’s mechanical survival rate is the closest thing we have to a durability rating. Patients care about it, and so should the people who buy the inventory.”

What I’d tell another administrator facing the same spreadsheet

It took me about a year and three real procurement mistakes to learn that price is a consequence of good specifications, not a substitute for them.

Now I start with a question that sounds almost too simple: What clinical problem are we trying to solve? For digital radiography, it wasn’t “buy a new X-ray machine.” It was “reduce technologist steps and get images in front of the radiologist faster.” For the surgical robot, it was “can we make prostate cancer surgery less invasive without destroying the practice’s operating budget?” For the Coloplast Titan, it was “which device gives our patients the best chance of long-term mechanical function and the fewest return trips to the operating room?”

Looking back, I should have asked those questions before I collected quotes. At the time, price felt objective and clinical evidence felt like someone else’s job. It’s actually the reverse. Evidence gets you to the right product. Price only tells you how much the wrong product costs.

I don’t have a perfect system now. I still make spreadsheet mistakes, and I still occasionally trust a smooth-talking rep for too long. But I no longer let a vendor’s line-item price be the loudest voice in the room. The finance director’s question about the Coloplast Titan embarrassed me into becoming a better buyer. If you’re an administrator, a practice manager, or anyone else who gets pulled into medical device purchasing, I’d rather you learn that lesson from this article than from a live meeting.

Bottom line: ask the outcome question first. The answers will tell you which vendor, which product, and which price deserve your signature.